ipharmacenter Consulting services

Merck announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa) in combination with Padcev (enfortumab vedotin) for the perioperative treatment of adults with muscle‑invasive bladder cancer (MIBC) who are ineligible for cisplatin‑based chemotherapy. The regimen includes neoadjuvant therapy before surgery followed by adjuvant treatment after cystectomy. These approvals mark the

Novartis has released new financial targets, forecasting annual sales growth of 5–6% at constant currencies from 2025 through 2030. This updated mid-term outlook extends the recent upward revision for 2024–2029, now set at a 6% constant currency compound annual growth rate (CAGR). The company anticipates growth in its oncology business to play a key role in driving revenue. Novartis has lifted the peak sales projections for its cancer therapies Kisqali and Scemblix, with the